Effect of UFT against oral cancers. Clinical effect and concentration of drug in tumor tissue.:Clinical effect and concentration of drug in tumor tissue

概要

論文の詳細を見る
Antitumor effect of UFT against human oral and maxillary cancers was examined clinically and biochemically. UFT therapy was carried out in 26 patients having primary or recurrent tumors in a daily dose of 300-600mg. The average period was 132.1 days and the average dose was 71.4g. UFT therapy was combined with operation and/or radiotherapy in 20 cases, and 6 cases were treated for adjuvant chemotherapy.<BR>In preoperative administration, clinical response was observed in one case out of 5 evaluable cases (20%). When UFT therapy was combined with radiotherapy in five cases, tumors were diminished completely in every case. The survival rate of 24 cases was 76.5% in 30 months in those to whom UFT was administered for 4 weeks or more.<BR>5-FU levels in the serum and the tumor tissues were examined in 4 cases. 5-FU levels in the tumor tissues were 0.081-0.166 mcg/g and these were reached 6-27 times of the serum one.<BR>Side effects were observed in 8 cases (30.8%), mainly digestive symptom, bone marrow supression and liver disfunction. However, these were generally mild, only in 2 cases administration of UFT was stopped due to the side effects.<BR>It is considered that UFT can be administered to oral cancer patients usefully and safely.